Actemra IV (tocilizumab) / Roche, JW Pharma, Cipla, Chugai Pharmaceutical - LARVOL DELTA

A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma (ASH 2025) - P1, P1/2 | "Here, we report the combined data of these twostudies to provide long term follow up data of GC012F/AZD0120 in NDMM pts.Methods Eligible NDMM pts received a single infusion of GC012F/AZD0120 following two cycles lenalidomide,bortezomib and dexamethasone (RVd) induction therapy...GC012F/AZD0120 was administered at 4 dose levels:1x105/kg (n=1), 1.5x105/kg (n=3), 2x105/kg (n=4), or 3x105/kg (n=22) after a standard 3-daylymphodepletion regimen of fludarabine and cyclophosphamide...3 pts were treated with one dose of tocilizumab and 1 pt was treated with one dose oftocilizumab and corticosteroids...These promising results highlight the potential ofGC012F/AZD0120 CAR-T therapy for treating NDMM patients with HR features and transplant ineligibleNDMM pts. Further research with a larger patient population and extended follow-up is needed tovalidate these findings and address this critically unmet medical need."

Clinical • Hematological Malignancies • Inflammation • Multiple Myeloma • Plasmacytoma • PLAAT3

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. (PubMed, J Clin Oncol) - P3 | "Mosun-Pola demonstrated superior efficacy verus R-GemOx, with significant improvements in both overall response rate and progression-free survival, and infrequent cytokine release syndrome events with a manageable safety profile.(Funded by F. Hoffmann-La Roche Ltd; ClinicalTrials.gov, NCT05171647)."

Journal • P3 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

MRD-Guided Frontline T-Cell Redirection Therapy for Newly Diagnosed High-Risk Multiple Myeloma Using Teclistamab-Daratumumab Intensification and Talquetamab-Daratumumab Early Rescue Intervention (IMS 2026) - P2 | "To evaluate the safety and preliminary efficacy of teclistamab-daratumumab (Tec-D) intensification following daratumumab-bortezomib-lenalidomide-dexamethasone (D-VRd) induction in ND-HRMM...CRS occurred in 7 patients (25%), all grade 1; only one required tocilizumab... Early MRD-guided incorporation of Tec-D intensification induced deep responses and high MRD-CR in ND-HRMM, supporting the evaluation of a full-immune based bispecific antibody-based, transplant-free approach in difficult to treat high-risk disease."

Late-breaking abstract • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Pneumonia • Respiratory Diseases

Updated Safety and Efficacy of Ramantamig (Ram; JNJ-5322) at the Recommended Phase 2 Dose (RP2D), Demonstrating Feasibility of Outpatient Dosing (OPD) in Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - P1 | "The OPD cohort (subset of RP2D cohort) was to receive all doses outpatient, including SUD and tx dose 1; prophylactic tocilizumab (ppx toci) was recommended. Longer follow-up of Ram monotherapy at the RP2D continues to demonstrate deep, durable responses in TCE RRMM with no new safety signals. OPD at start of tx was feasible with low-gr, manageable CRS using ppx toci. The safety profile and convenient schedule (single SUD dose, fixed Q4W dosing) support use of this novel dual myeloma-antigen targeting Ab across practice settings."

Clinical • First-in-human • P2 data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Pruritus • Thoracic Cancer

A Fixed-Duration, Modified Cevostamab Dosing Regimen Induces Durable Remissions That Continue After Completion in BCMA-Na�ve Pts With Relapsed/Refractory Multiple Myeloma (RRMM): CAMMA 1 Arm a Results (IMS 2026) - P1 | "CRS was managed with tocilizumab in 7 pts and steroids in 4 pts. A fixed-duration, modified cevostamab dosing regimen induces durable remissions that continue after treatment completion in BCMA-naïve pts with RRMM. Safety was manageable. Exposure-response analyses evaluating the relationship between the modified regimen, VGPR+ rates and DOR are ongoing and will be presented, as will data on B-cell recovery kinetics."

Clinical • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Leukemia • Multiple Myeloma • Neutropenia • Pneumonia • Rare Diseases • Respiratory Diseases • Septic Shock

Retained epcoritamab activity despite routine CD20 assay negativity approximately one terminal half-life after mosunetuzumab in B-cell lymphoma. (PubMed, J Clin Exp Hematop) - "During step-up dosing, grade 1 cytokine release syndrome resolved after one dose of tocilizumab. These findings suggest that negative CD20 results by routine assays shortly after mosunetuzumab therapy do not necessarily reflect true target loss. Integrated interpretation of histopathology, flow cytometry, and clonality studies may help guide subsequent CD20-directed treatment decisions."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CD79A • IL2 • PAX5

Successful treatment of cryoglobulinemic Vasculitis with Upadacitinib (EADV 2026) - "Due to refractory RA activity under tocilizumab, therapy was switched to abatacept...Under therapy with upadacitinib (15 mg daily), low-dose prednisolone, and tinzaparin, rapid clinical improvement was observed...Conclusion Management of type III cryoglobulinaemic vasculitis typically targets autoimmune B-cell activity, using glucocorticosteroids and, in severe cases, rituximab or cyclophosphamide...JAK inhibitors may represent a promising alternative in patients with limited treatment options. Further studies are warranted to evaluate their efficacy and safety in cryoglobulinaemic vasculitis."

ANCA Vasculitis • Complement-mediated Rare Disorders • Hepatology • Infectious Disease • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Vasculitis

Tocilizumab for refractory cerebral arteritis in a patient with systemic lupus erythematosus: A case report. (PubMed, Mod Rheumatol Case Rep) - "Despite treatment with high-dose glucocorticoids, intravenous cyclophosphamide, mycophenolate mofetil, and anifrolumab, the disease remained progressive with persistently elevated C-reactive protein (CRP) levels and worsening arterial stenosis on magnetic resonance angiography (MRA). TCZ might be a viable treatment option for refractory cerebral arteritis in patients with SLE, particularly in cases of elevated cerebrospinal fluid IL-6 levels. To our knowledge, this is the first reported case suggesting the potential efficacy of TCZ in SLE-related cerebral arteritis."

Journal • CNS Disorders • Immunology • Inflammatory Arthritis • Lupus • Psychiatry • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • CRP • IL6

Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressing an anti-CD30-chimeric antigen receptor with 4-1-BB and CD3z costimulatory sequences in patients with Classical Hodgkin lymphoma and non-Hodgkin CD30+ T cell lymphoma. (clinicaltrialsregister.eu) - P1/2 | N=40 | Active, not recruiting | Sponsor: Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau | Recruiting ➔ Active, not recruiting

Enrollment closed • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • ALK • TNFRSF8

Diffuse Cutaneous Desquamation Following Tocilizumab in an Adolescent with Multisystem Sarcoidosis (EADV 2026) - "She had previously been treated with systemic corticosteroids, methotrexate, and infliximab, and was currently receiving tocilizumab at a dose of 400 mg/month. Conclusion This case highlights that diffuse cutaneous desquamation, although non-severe, may occur in children receiving tocilizumab even after initial tolerance. Dermatological monitoring and appropriate premedication are essential to ensure safe continuation of therapy."

Immunology • Sarcoidosis • IL6

Lichen planopilaris in a 6-year-old child exacerbated after a hair straightening treatment (EADV 2026) - "Other therapies reported in the literature may involve calcineurin inhibitors, topical minoxidil, and tocilizumab. In refractory cases, systemic treatments can be considered, including oral corticosteroids, methotrexate, cyclosporine, tetracyclines, mycophenolate mofetil, and Janus kinase inhibitors. LPP is a rare condition in children, but it should be considered in any cicatricial alopecic patch in order to ensure early diagnosis and appropriate management."

Clinical • Alopecia • Fibrosis • Immunology • Inflammation • Lichen Planus • Pruritus

Paradoxical Psoriasis Induced by Anakinra in a Child with Systemic Juvenile Idiopathic Arthritis (EADV 2026) - "She was initially treated with tocilizumab (Actemra®) associated with low-dose corticosteroid therapy (prednisone 5 mg/day). Conclusions This case highlights a rare cutaneous adverse event induced by Anakinra in a pediatric patient with systemic JIA. Early recognition of paradoxical psoriasiform reactions during biologic therapy is important to optimize therapeutic management and prevent disease progression."

Clinical • Dermatology • Idiopathic Arthritis • Immunology • Lupus • Psoriasis • Rheumatology

Beyond the Flare: Mycobacterium tuberculosis as an Opportunistic Threat in VEXAS Syndrome (EADV 2026) - "After UBA1 mutation confirmed VEXAS, he received anakinra (discontinued due to allergic reaction), tocilizumab, and pulse corticosteroids...MTB complex DNA was detected by PCR in synovial fluid and bronchoalveolar lavage; culture confirmed isoniazid-resistant MTB and quadruple therapy (rifampicin, ethambutol, pyrazinamide, moxifloxacin) was initiated. Co-infections with Kluyveromyces marxianus and Magnuciomyces capitatus required voriconazole...Prophylactic strategies targeting Pneumocystis jirovecii pneumonia (PJP) and varicella zoster virus (VZV) have proven effective; analogous vigilance for MTB, including latent tuberculosis screening and prophylaxis where indicated, should be implemented in endemic settings. Cutaneous manifestations may represent the earliest findings in VEXAS; however, concurrent opportunistic infections — including MTB — may complicate the disease course and must be recognised and managed promptly."

Aplastic Anemia • Hematological Disorders • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Nontuberculous Mycobacterial Disease • Pneumonia • Respiratory Diseases • Septic Shock • Tuberculosis • Varicella Zoster • Vasculitis

BCMA-Targeted T-Cell Engager Therapy Induces Rapid and Durable Remission in Refractory Pemphigus (EADV 2026) - "Both were refractory to rituximab and had received mycophenolate mofetil as their last therapy, discontinued three weeks prior to teclistamab to allow T-cell recovery...Both patients experienced grade 1 cytokine release syndrome after the second dose, resolving promptly under treatment with tocilizumab and paracetamol, respectively...Adverse effects were manageable with close monitoring. These results support teclistamab as a promising therapy for refractory pemphigus and warrant evaluation in larger cohorts."

Clinical • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Otorhinolaryngology • Respiratory Diseases

Systemic sclerosis and cutaneous lupus erythematosus overlap (EADV 2026) - "The patient was under long ‑ term treatment and follow ‑ up including biologic therapy with Tocilizumab for systemic sclerosis...Conclusion Our case confirms the rarity and diagnostic challenge of systemic sclerosis-cutaneous lupus erythematosus overlap, particularly in a patient with long ‑ standing, biologic ‑ treated SSc and severe vasculopathic damage. The coexistence of these disorders underscores the need for thorough clinicopathological correlation to achieve an accurate diagnosis and to guide appropriate, multidisciplinary management."

Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Scleroderma • Systemic Sclerosis

Canakinumab-associated suppression of an mTOR-related serum proteomic signature after switching from tocilizumab in Still's disease. (PubMed, Rheumatology (Oxford)) - No abstract available

Journal • Immunology

Liquid biopsy of cancer-associated fibroblasts (CAFs) and tumor fibrosis for assessment of response and survival in pancreas cancer patients treated with Nivolumab/radiotherapy ± Ipilimumab or Gemcitabine/Nab-Paclitaxel ± Tocilizumab (ESMO 2026) - No abstract available

Biopsy • Clinical • Liquid biopsy • Oncology • Pancreatic Cancer • Solid Tumor • CAFs

A phase 1 study of in situ Immunomodulation with CDX-301, radiotherapy, CDX-1140, and Poly-ICLC ± pembrolizumab and tocilizumab – Safety and preliminary antitumor activity in patients with unresectable and metastatic solid tumors (ESMO 2026) - No abstract available

Clinical • Immunomodulating • Metastases • P1 data • Oncology • Solid Tumor

Interpretable machine learning models for predicting tocilizumab response in rheumatoid arthritis using clinical data. (PubMed, BMC Med Inform Decis Mak) - "This study demonstrates the potential of machine learning to predict TCZ treatment outcomes and identify stage-specific features in patients with RA."

Clinical data • Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Tocilizumab, atezolizumab, and stereotactic radiotherapy in recurrent glioblastoma: primary analysis of safety and efficacy of a phase 2 trial, NRG Oncology-BN010. (PubMed, Int J Radiat Oncol Biol Phys) - "These findings suggest that the combination of tocilizumab, atezolizumab, and FSRT was safe and well tolerated in patients with rGBM but did not achieve the pre-specified efficacy outcome."

Journal • P2 data • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010 (ASH 2025) - "Tocilizumab was administered prophylactically in the latter two patients after the first IRR was observed...No clinical sequelae of the lymphocytosis were noted; dexamethasone promptly resolved the lymphocytosis in the patient with the highest ALC... Preliminary results from the first three patients dosed in the inMMyCAR Phase 1 study of KLN-1010 demonstrate that promising clinical activity and manageable toxicities are feasible with an offthe-shelf in vivo CAR-T in MM. Lymphodepletion was not required for in vivo CAR-T cell generation and expansion in the peripheral blood. CRS was consistent with that seen with ex vivo CAR-T therapies, while cytopenias were notably limited and no treatment-emergent infections occurred."

First-in-human • Gene therapy • Late-breaking abstract • Minimal residual disease • P1 data • Preclinical • Residual disease • CNS Disorders • Dyslipidemia • Gene Therapies • Hematological Malignancies • Infectious Disease • Movement Disorders • Multiple Myeloma • Neutropenia • Parkinson's Disease • Thrombocytopenia

Beyond Anatomy: [ 18 F]FDG-PET/TC unveils Large Vessel Vasculitis (EANM 2026) - "Given the suspicion of LVV, an [18F]FDG-PET/TC was performed, which demonstrated intense hypermetabolism in the perivascular along the course of aorta (SUVmax10.92; TBR (target-to-background ratio) 8.6 using blood pool as background), supra-aortic trunks, and subclavian, iliac and femoral arteries, consistent with the clinical suspicion, with a PETVAS score of 27/27 and Total Vascular Score (TVS) of 21/21.Based on metabolic imaging reports, treatment with Prednisone and Tocilizumab was initiated. [18F]FDGPET/TC is recommended for the diagnosis, assessment of inflammatory activity and disease extent in LVV, and it was key in the diagnosis and management of our patient."

FDG PET • Cough • Inflammation • Respiratory Diseases • Vasculitis

FDG PET/CT in Adult-Onset Still's Disease: Whole-Body Metabolic Characterisation, Lymphoma Differentiation, and Treatment Response Monitoring (EANM 2026) - "In the treatment monitoring pair, post-treatment PET (methylprednisolone pulse, IVIg, etoposide, tocilizumab) showed marked metabolic response: LN SUVmax reduced by 78% (43.2 → 9.5), spleen by 59% (38.8 → 16.0), bone marrow by 62% (18.5 → 7.0), and joints by 75% (8.0 → 2.0), paralleling a 96% reduction in ferritin (66,917 → 2,629 ng/mL). FDG PET/CT in AOSD demonstrates a characteristic hypermetabolism with SUVmax strongly correlating with serum ferritin. PET adds critical value in differentiating AOSD from lymphoma and in objective treatment response monitoring."

Clinical • FDG PET • Hematological Malignancies • Immunology • Lymphoma

Comparative Effectiveness of Tocilizumab and Tumor Necrosis Factor Inhibitors in Takayasu Arteritis: Age-Related Differences in Treatment Response. (PubMed, Arthritis Care Res (Hoboken)) - "TNFi and TCZ demonstrate similar effectiveness in TAK. These findings support therapeutic switching after treatment failure and suggest that age-related immunologic differences may influence treatment response."

HEOR • Journal • Oncology • Vasculitis • CRP • IL6

Tocilizumab in Radiation-Induced Plexopathy (EANO 2026) - "After failure of bevacizumab, the patient received compassionate tocilizumab. Tocilizumab (162 mg every four weeks for three cycles) was well tolerated and led to partial clinical improvement, including increased muscle strength (≥1 point on MRC scale) and reduced paresthesias. This case highlights a potential disease-modifying role of IL-6 blockade in RIBP, including in late-stage or treatment-refractory cases. It supports further investigation of tocilizumab as a therapeutic option and suggests IL-6 as a relevant target in radiation-induced plexopathy."

Oncology • Sarcoma • Solid Tumor